4 weeks Lexicon Pharmaceuticals (LXRX) Reports Q4 Loss, Tops Revenue Estimates Zacks
Lexicon (LXRX) delivered earnings and revenue surprises of 18.18% and 215.37%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
X